More than 240 immuno-oncology treatments in development to fight cancer
By Andrew Powaleny | June 1, 2017
The American Cancer Society estimates that in 2017 alone, there will be more than 1.6 million new cases of cancer and 600,000 cancer deaths in the United States. With estimates like these, the...
Read More
Medicines have significantly increased chances of cancer survival around the globe
By Amey Sutkowski | May 24, 2017
Since a peak in 1991, cancer mortality rates have declined by as much as 27% around the world. These gains in cancer survival are largely attributed to new and innovative therapies. According to...
Read More
Fighting disease Together: New ads feature patients and the researchers behind today’s breakthroughs
By Robert Zirkelbach | April 19, 2017
Today, we launched our next wave of advertising as part of the GOBOLDLY™ campaign, titled Together, featuring the stories of researchers developing cutting-edge breakthroughs alongside patients...
Read More
ICYMI: Report highlights overall decrease in cancer death rates
By Andrew Powaleny | April 3, 2017
In case you missed it, cancer death rates are continuing to decrease for men, women and children in the United States thanks in part to biopharmaceutical innovation, according to the Annual Report...
Read More
This is not a video game: New TV ad showcases the destruction of a cancer cell by immune system
By Robert Zirkelbach | February 5, 2017
Today, as part of our new advertising and public affairs initiative, GOBOLDLY™, we are excited to announce the premier of our newest TV advertisement, Cells, which highlights innovative...
Read More
The 20-year journey yielding a new weapon against cancer
By Andrew Powaleny | January 10, 2017
Developing new medicines is a long, complex process. On average, it takes at least 10-12 years for a new medicine to complete the journey from initial discovery to becoming part of a patient’s...
Read More
Significant progress fighting cancer: Death rate has dropped 25 percent
By Holly Campbell | January 9, 2017
Cancers have long been one of the most devastating and complex disease areas facing patients. But thanks in part to innovative advancements in treatments and early detection, the cancer death rate...
Read More
Video: Translating science into new medicines
By Andrew Powaleny | December 12, 2016
Researchers and scientists at America’s biopharmaceutical companies and around the globe work every day to translate science into new treatments and cures to allow patients to live longer,...
Read More
Building on the promise of personalized medicine
By Andrew Powaleny | November 16, 2016
PhRMA’s member companies are on the leading edge of personalized medicine development– an area that is transforming health care, improving patient outcomes and creating health system efficiencies....
Read More
ICER puts hard-fought progress in non-small cell lung cancer treatment at risk
By Holly Campbell | September 1, 2016
Lung cancer is the leading cause of cancer death among men and women in the United States, and each year, tens of thousands of Americans are diagnosed with the most common form, non-small cell...
Read More
Medicare Monday (100)
340B Spotlight (36)
Cost & Consequence (0)
